ASCO 2023
ASCO 2023
Advertisement
Rob DillardASCO 2023 | September 5, 2023
A study aimed to validate the use of the Molecular International Prognostic Scoring System for myelodysplastic syndromes.
Read More
Rob DillardASCO 2023 | September 26, 2023
Treatment using a BET inhibitor as a monotherapy and in combination with appears well-tolerated in myelofibrosis.
Patrick DalyASCO 2023 | June 15, 2023
Real-world outcomes were comparable to clinical trials in breast cancers with BRCA mutations treated with PARP inhibitors.
Patrick DalyASCO 2023 | June 15, 2023
A cohort analysis found abbreviated breast MRI was an effective for cancer screening in patients with dense breasts.
Patrick DalyASCO 2023 | June 15, 2023
Patients with DCIS breast cancer had "excellent disease control" after lumpectomy and accelerated partial breast irradiation.
Patrick DalyASCO 2023 | June 15, 2023
Results from the 21-gene Breast Recurrence Score commercial assay were successful predictors for cancer-specific mortality.
Rob DillardASCO 2023 | October 27, 2023
Researchers used a radiomics approach to predict brain metastases in lung cancer patients.
Rob DillardASCO 2023 | August 30, 2023
The bone marrow microenvironment of myelodysplastic syndromes is very different from that of acute myeloid leukemia.
Rob DillardASCO 2023 | June 22, 2023
Middle meningeal artery embolization is a novel, minimally invasive strategy that may help manage subdural hematomas in AML.
Rob DillardASCO 2023 | August 30, 2023
Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes.
Dr. Ruben MesaASCO 2023 | September 26, 2023
Ruben Mesa, MD, spoke at ASCO 2023 about the affect myelofibrosis has on patients’ quality of life.
Oncology BrothersOncology Brothers | August 11, 2023
The Oncology Brothers were live at ASCO 2023 to discuss findings from the TROPiCS-02 study.
Oncology BrothersOncology Brothers | November 8, 2023
The Oncology Brothers discuss findings from the phase 3 ADAURA trial.
Dr. Patrick FordeASCO 2023 | September 21, 2023
Dr. Patrick Forde spoke with DocWire News at ASCO 2023 about updated data from the CheckMate 816 trial.
Rob DillardASCO 2023 | August 25, 2023
Pelabresib monotherapy appears to be clinically beneficial in patients who have high-risk essential thrombocythemia.
Rob DillardASCO 2023 | February 29, 2024
Ruxolitinib is effective at controlling hematocrit in the majority of patients with polycythemia vera.
Rob DillardASCO 2023 | August 25, 2023
The up-regulation of glutaminase is a common feature in Philadelphia-negative and JAK2-V617F-driven MPNs.
Rob DillardASCO 2023 | September 26, 2023
Zilurgisertib appears safe and well tolerated in patients who have anemia due to myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
A proof-of-concept study indicates the combined use of ruxolitinib and magrolimab is effective in treating myelofibrosis.
Rob DillardASCO 2023 | September 26, 2023
The treatment combination of selinexor plus ruxolitinib is effective in treatment-naïve patients with myelofibrosis.
Advertisement
Advertisement
Advertisement
Latest News

March 1, 2024